BridgeBio Pharma (BBIO) P/B ratio
Only 1 fiscal year of P/B ratio is on record here for BridgeBio Pharma (BBIO); a history needs at least 3. Figures as of 18 Nov 2026, 11:44 UTC, from the company's filings with the SEC and Yahoo Finance.
Key facts
- P/B ratio, fiscal 2020
- 144.9×
- Fiscal years on record
- 12020–2020
Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.
Not enough data
A history of P/B ratio needs at least 3 fiscal years; one is on record here for BridgeBio Pharma. Nothing is estimated to fill the gap. What is on record is in the table below.
BridgeBio Pharma P/B ratio, year by year
| Fiscal year | P/B ratio | Change | Year ended | Share price at year-end | Book value per share |
|---|---|---|---|---|---|
| 2025 | — | — | $76.49 | -$10.89 | |
| 2024 | — | — | $27.44 | -$7.89 | |
| 2023 | — | — | $40.37 | -$8.32 | |
| 2022 | — | — | $7.62 | -$8.51 | |
| 2021 | — | — | $16.68 | -$6.03 | |
| 2020 | 144.9× | — | $71.11 | $0.49 | |
| 2019 | — | — | $35.05 | — |
Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
The P/B ratio is the share price divided by book value per share — shareholders' equity on the balance sheet divided by the share count — at each fiscal year-end; a year with negative equity has no P/B.
How to read it
It compares the price with the accounting value of what the company owns net of what it owes, and matters most for banks, insurers and other balance-sheet businesses.
P/B ratio at health care companies of similar size
| Company | P/B ratio |
|---|---|
| Summit Therapeutics SMMT | 13.0× |
| Glaukos GKOS | 21.9× |
Today's market value divided by shareholders' equity at the latest fiscal year-end. A company whose statements are in another currency than its shares is left out.
BridgeBio Pharma, figure by figure
- BridgeBio Pharma market cap
- BridgeBio Pharma revenue
- BridgeBio Pharma earnings
- BridgeBio Pharma earnings per share (EPS)
- BridgeBio Pharma P/E ratio
- BridgeBio Pharma P/S ratio
- BridgeBio Pharma free cash flow
- BridgeBio Pharma operating margin
- BridgeBio Pharma dividend
- BridgeBio Pharma shares outstanding
- BridgeBio Pharma total debt
- BridgeBio Pharma cash on hand
- BridgeBio Pharma total assets
- BridgeBio Pharma return on equity (ROE)
- BridgeBio Pharma return on invested capital (ROIC)
BridgeBio Pharma (BBIO) overview: price, valuation and scorecardAll health care companies by market value
BridgeBio Pharma P/B ratio: questions and answers
How is BridgeBio Pharma's P/B ratio calculated?
The P/B ratio is the share price divided by book value per share — shareholders' equity on the balance sheet divided by the share count — at each fiscal year-end; a year with negative equity has no P/B.
Share prices are Yahoo Finance's monthly closes: a fiscal year-end is paired with the close of the month it falls in, and today's quote may be delayed. Fiscal years are named for the calendar year they end in.
Learn: P/B ratio
All stocks guides →- P/E ratio explained: what a high or low figure means
The price-to-earnings (P/E) ratio is a share's price divided by its earnings per share. A stock at $100 earning $5 a share has a P/E of 20: buyers pay $20 for each dollar of yearly profit. A high P/E usually means the market expects profit to grow; a low one can mean doubt, not a bargain.
- Piotroski F-score: the nine tests and what they show
The Piotroski F-score is a 0–9 count of simple accounting tests a company passes: four on profitability, three on debt, liquidity and share issuance, two on operating efficiency. Joseph Piotroski's 2000 paper found that among cheap, high book-to-market stocks, high scorers went on to beat low scorers. It is a screen of financial health, not a valuation.
- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
Cite this page
Funkfolio, “BridgeBio Pharma (BBIO) P/B ratio”, data as of 18 November 2026. https://funkfolio.com/stock/BBIO/pb-ratio
Underlying data: the company's filings with the SEC and Yahoo Finance.